InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis.

Byadmin

SHANGHAI, Nov. 2, 2026 /PRNewswire/ — InventisBio Co., Ltd. today announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key secondary endpoint in a registrational Phase III clinical trial for the treatment of moderate-to-severe plaque psoriasis, demonstrating clinically and statistically significant superiority over placebo. This result marks a milestone…

InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis

Byadmin

SHANGHAI, Dec. 3, 2024 /PRNewswire/ — InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to severe plaque psoriasis. The randomized, multicenter, double-blind, placebo-controlled study demonstrated that D-2570 achieved significant efficacy in improving skin clearance while maintaining a favorable safety…